



The VMP Regulation in 2022 and beyond

Veterinary Medicines Info Day 2021

Dr. Eva ZAMORA ESCRIBANO
Head of Unit Animal Nutrition, Veterinary Medicines,
Health and Food Safety Directorate-General

Regulation (EU) 2019/6 of
the European Parliament and
of the Council of 11
December 2018 on
veterinary medicinal
products and repealing
Directive 2001/82/EC

VMP Regulation

AHL

F2F
Strategy

Modern
innovative

Fit-for-
purpose

Fight
against
AMR

Easier and
faster
access to
data

Limited
Markets

Consumer
confidence

Streamlined
procedures
and
processes

Increase
availability
of VMPs

Stimulate
innovation



Reduce
administrative
burden

More
transparency
and info on
all VMPs in
the Union



European
Commission

Legislative procedures



Where can you follow progress?

On our dedicated web page:

<https://europa.eu/!rJ63kT> or QR code →




Where can you provide feedback?

On the Have Your Say platform:

<https://ec.europa.eu/info/law/better-regulation/have-your-say>

Already in force
Applies 28/01/2022

VMP Regulation 2022



To be adopted by 2025
or as necessary (*)

VMP Regulation Beyond 2022

List of substances
for off-label use
in food-producing
aquatic species

List of
substances
essential for
equine species

Uniform rules
on the
identification
code

Rules for the
functioning of the
worksharing
procedure*

Procedures for
financial penalties
for CAs VMP

List of AM not to
be used off label*

Model format for
prescriptions*

Rules for VMP
oral
administration via
drinking water or
top dressing

GMPs VMPs &
active substances

Rules on the size of
small immediate
packaging units

Abbreviations
and pictograms
for labelling

11 legal acts

Applications



EP/Council

Requirements on technical documentation necessary for demonstrating the quality, safety and efficacy of VMPs – Annex II

Updated requirements for dossier for marketing authorisations

Reduction of administrative burden and increasing the availability

New rules for biological and novel therapy VMPs – to promote product innovation and development

Addresses issues related to the development of AMR

New/updated provisions for:

- Vaccine antigen master file
- Vaccine platform technology*
- Multi-strain dossier (viral & bacterial)

Defines reduced data requirements for limited markets and applications in exceptional circumstances

Contribution to the F2F Strategy
Reduction of the EU overall
sales of AM by 50% in 2030

One Health
approach

Antimicrobial Resistance Prudent Use

Public
feedback

Criteria to designate AM
reserved for humans
only

List of AM reserved
for human use

Imports of animals
and products of
animal origin

Drafting

Preserving the efficacy of AM –
public health / animal health
Longer “viability” on the market

Medium term



Prohibition of certain uses or the use
of certain AM applicable to imports
from third countries

**Initiate discussions on new business models, economic or regulatory
incentives that are financially sustainable for:**

- **development of new AM/alternatives for the veterinary market**
- **maintenance of supply of existing AM for the veterinary market**

Contribution to the F2F Strategy
Reduction of the EU overall
sales of AM by 50% in 2030

Antimicrobial Resistance Monitoring & Risk Management

EP/Council

Requirements for the
collection of data on
sales and use of AM


Format for the
collection of data on
sales and use of AM

Under
Discussion
MS

Targeted measures

Provides a good overview of the EU market landscape,
overall EU and per Member State, on sales of AM used in
animals and on use of AM per animal species (food
producing animals and other animals kept or bred)

⇒ Valuable information for the industry



Post-marketing authorisation measures

Published
O.J.

Union Product
Database

- Enhance the Single market by providing info on existing VMPs and their availability per Member State
- Help vets elaborate treatment alternatives
- Future-proof by continuous evolution involving MAH feedback
- Aimed at avoiding duplicate input of info
- Reducing admin burden, e.g. by allowing grouping changes

Variations
not requiring
assessment

- New category of “variations”
- Easy procedure for recording changes to a VMP that do not need to be assessed by NCAs
- Reduction of administrative burden

Good
Pharmacovigilance
Practice & PSMF

Under
discussion
MS

- Create an efficient system of continuous surveillance
- Pharmacovigilance database
- Better info for users (SPC+PL)
- Increased consumer confidence in safe VMPs

UPDATE ON IMPLEMENTATION: OUTLOOK AND WAY FORWARD

- Overall, the work is progressing on time
- The Commission maintains its ambition for timely implementation
- The Commission relies on the continued commitment of the Agency, the Member States and stakeholders so that we can make the implementation of the VMP Regulation a success

Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com

